KR20210114897A - A cosmetic composition for promoting skin beneficial bacteria - Google Patents

Abstract

The present invention relates to a composition for promoting beneficial skin bacteria including as an active ingredient one or more substances selected from a group consisting of Centella asiatica extracts, Avena sativa extracts, Arnica montana extracts, Allantoin, black ginseng extracts or a fraction thereof, red ginseng extracts or a fraction thereof, tyrosine and combinations thereof. The Centella asiatica extracts, Avena sativa extracts, Arnica montana extracts, Allantoin, black ginseng extracts or a fraction thereof, red ginseng extracts or a fraction thereof, tyrosine and combinations thereof according to the present invention exhibit a beneficial skin bacteria enhancing effect, thereby being provided as a cosmetic or pharmaceutical composition for promoting beneficial skin bacteria.

Description

A cosmetic composition for promoting skin beneficial bacteria

The present invention relates to any one or more substances selected from the group consisting of Centella asiatica extract or fraction thereof, oat extract or fraction thereof, arnica extract or fraction thereof, allantoin, black ginseng extract or fraction thereof, red ginseng extract or fraction thereof, tyrosine and combinations thereof. It relates to a composition for promoting skin beneficial bacteria comprising as an active ingredient. The composition may be provided as a cosmetic or pharmaceutical.

A properly functioning skin barrier is an essential part of human health (Prescott et al. World Allergy Organization Journal (2017) 10:29). Keratinocytes in the stratum corneum, a component of the skin barrier, play an important role in adapting the entire body by producing hormones and neurotransmitters cytokines when the external environment changes. In doing this, the skin microbes help keratinocytes mature and influence the regulation of the body's immune system. Therefore, changes in microorganisms in the skin can cause skin diseases as well as other non-communicable diseases (NCD). In fact, it is known that the disturbance of microorganisms in the stratum corneum is associated with skin allergies, psoriasis, redness, acne, skin aging, and the like.

The strains mainly inhabiting the human skin are Firmicutes ( Firmicutes ), Bacteroidetes ( Bacteroidetes ), Proteobacteria ( Proteobacteria ) and Actinobacteria ) Four species. However, even within a single individual, the composition of skin microorganisms varies greatly in each environment. For example, in an oily area, a lot of Propionibacteria and Staphylococci species inhabit, in a wet area a lot of Corynebacteria and Staphylococcus species, and in a dry area, beta with several species. -Proteobacteria ( beta-Proteobacteria ) and Flavobacteriale (flavobacteriale) species mainly inhabit. As such, the strain inhabiting the skin is different for each individual, and may vary according to the nutritional status, health, age, and surrounding environment of each individual.

Among them, Staphylococcus epidermidis constitutes more than 90% of the aerobic environment. This bacterium has anti-inflammatory properties and helps to act as a barrier to prevent the growth of pathogenic bacteria such as Staphylococcus aureus strains. The mechanism of action of S. epidermidis is to prevent the production of cytokines, which are inflammatory substances, by producing antibacterial peptides, Bacteriocins, and also to strengthen the skin barrier in a way that helps the expression of tight junction proteins. It helps the immune system. These actions are mediated through innate immune receptors on keratinocytes and other immune cells. Therefore, like other organs, the skin's innate immune system is made due to the interaction between humans and microorganisms, which is an important factor in the homeostasis control of skin immunity.

Accordingly, if the growth of Stephylococcus epidermidis, which is a skin flora and beneficial bacteria, can be improved, the skin condition can be improved. As a cosmetic material, there is an increasing demand for the development of substances that can exhibit this beneficial bacteria promoting effect. .

Under this background, the present inventors have completed the present invention by identifying natural products having an effect of promoting beneficial skin bacteria as a result of intensive efforts to develop a composition for promoting beneficial skin bacteria, such as S. epidermidis.

An object of the present invention is any one selected from the group consisting of Centella asiatica extract or fraction thereof, oat extract or fraction thereof, arnica extract or fraction thereof, allantoin, black ginseng extract or fraction thereof, red ginseng extract or fraction thereof, tyrosine and combinations thereof It is to provide a composition for promoting beneficial skin bacteria comprising the above as an active ingredient.

Another object of the present invention is to provide a cosmetic composition comprising the composition.

Another object of the present invention is to provide a pharmaceutical composition for promoting skin beneficial bacteria comprising the composition.

This will be described in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be considered that the scope of the present invention is limited by the specific descriptions described below.

One aspect of the present invention for achieving the above object is Centella asiatica extract or fraction thereof, oat extract or fraction thereof, arnica extract or fraction thereof, allantoin, black ginseng extract or fraction thereof, red ginseng extract or fraction thereof, tyrosine and combinations thereof It provides a composition for promoting beneficial skin bacteria, comprising any one or more selected from the group consisting of as an active ingredient.

The composition may include one or more, two or more, three or more, four or more, five or more, six of the above six substances, but is not limited thereto.

In one embodiment, the composition may include Centella asiatica extract or a fraction thereof, but is not limited thereto.

In one embodiment, the composition may include an oat extract or a fraction thereof, but is not limited thereto.

In one embodiment, the composition may include an arnica extract or a fraction thereof, but is not limited thereto.

In one embodiment, the composition may include allantoin, but is not limited thereto.

In one embodiment, the composition may include a black ginseng extract or a fraction thereof, but is not limited thereto.

In one embodiment, the composition may include a red ginseng extract or a fraction thereof, but is not limited thereto.

In one embodiment, the composition may include tyrosine, but is not limited thereto.

The term "Centella asiatica " of the present invention is a perennial herb of the Umbelliferae family of the umbelliferous family. In the present invention, the Centella asiatica may use roots, stems, leaves, fruits, flowers, etc., dried products or processed products thereof, and in particular, leaf parts may be used, but the present invention is not limited thereto. The term "oat" in the present invention ( Avena sativa , Oat)" is a herbaceous perennial herb of the genus oleifera, used in cooking, as a raw material for alcohol and confectionery, or as feed for livestock. The kernel of oats is called Avena sativa kernel. In the present invention, the oats may use roots, stems, leaves, fruits (grains), flowers, and dried or processed products thereof, and in particular, grainy oat kernels may be used, but the present invention is not limited thereto.

The term "Arnica montana " of the present invention is a perennial plant belonging to the Asteraceae, and the component contained in its flower is known to facilitate blood circulation. In the present invention, the arnica may use roots, stems, leaves, fruits, flowers, etc., dried products or processed products thereof, and in particular, flower parts may be used, but the present invention is not limited thereto.

As used herein, the term "Allantoin (Allantoin) is a natural substance extracted from the buds of comfrey, oak, and wheat, which are perennial grasses, and is also called 5-ureidohydantoin. Eureide of glyoxylic acid is a compound.

As used herein, the term "black ginseng" refers to ginseng in which ginseng has turned black through several steaming and drying processes. However, it is known that the content of ginseng saponin present only in processed ginseng is enhanced. In the present invention, the black ginseng may be black ginseng itself or fermented black ginseng, but is not limited thereto.

The fermented black ginseng may be prepared by fermenting with a strain usable for conventional fermentation. The strain may be used without limitation as long as it is a strain used for fermentation known in the art, and may be, for example, lactic acid bacteria, yeast or mold.

Specifically, the strain is Bifidobacterium (Bifidobacterium) spp, Lactobacillus bacteria (Lactobacillus) spp, Lactococcus (Lactococcus) sp, flow Pocono stock (Leuconostoc) sp, Phedi O Rhodococcus (Pediococcus) sp, Streptomyces Lactic acid bacteria such as Streptococcus sp. strains; Saccharomyces sp. strain, Shijo Saccharomyces sp. strain, Jigo Saccharomyces sp. strain, Hansenula sp. strain, Bretanomyces sp. strain, Decera sp. strain, Streptomyces sp. strain, etc. leaven; Or Aspergillus genus ( Aspergillus ) strain, Monascus ( Monascus ) Fungi such as sp. strain; may be, may be a Lactobacillus genus or Saccharomyces sp. strain, but is not limited thereto.

More specifically, the strain is Bifidobacterium bifidum ( Bifidobacterium bifidum ), Bifidobacterium breve ( Bifidobacterium breve ), Bifidobacterium longum ( Bifidobacterium longum ), Bifidobacterium animalis ( Bifidobacterium animalis ), Bifidobacterium animalis Bifidobacterium lactis ( Bifidobacterium lactis ), Lactobacillus acidophilus ( Lactobacillus acidophilus ), Lactobacillus casei ( Lactobacillus casei ), Lactobacillus gasseri ( Lactobacillus gasseri ), Lactobacillus brueckii s pp Lactobacillus bruecki spp . , Lactobacillus bulgaricus ( Lactobacillus bulgaricus ), Lactobacillus helveticus ( Lactobacillus helveticus ), Lactobacillus fermentum ( Lactobacillus fermentum ), Lactobacillus paracasei ( Lactobacillus paracasei ), Lactobacillus plant Lactobacillus ( Lactobacillus paracasei ), Lactobacillus plant Lactobacillus Terry ( Lactobacillus reuteri ), Lactobacillus rhamnosus ( Lactobacillus rhamnosus ), Lactobacillus salivarius ( Lactobacillus salivarius ), Lactococcus lactis ( Lactococcus lactis ), leukonostok mecentenoides , Pediococcocococococcuss Leuconost Lactic acid bacteria such as Pediococcus cerevisiae , Pediococcus acidilactici , Streptococcus lactis , Streptococcus thermophiles , and Streptococcus cremoris; Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), Saccharomyces ellipsoideus ( Saccharomyces ellipsoideus ), Saccharomyces coreanus ( Saccharomyces coreanus ), Saccharomyces carlsbergensis , Saccharomyces carlsbergensis ) Saccharomyces pastorianus , Saccharomyces lactis , Saccharomyces rouxii , Schizosaccharomyces pombe , Zygosaccharomyces major ), Hansenula anomala ( Hansenula anomala ), Brettanomyces bruxellensis ( Brettanomyces bruxellensis ), Brettanomyces custersianus ), Deckera anomala ( Dekkera anomala ), Streptomyces olivok Yeasts such as lomogenes ( Streptomyces olivochromogenes ), Streptomyces griseus ( Streptomyces griseus ) and the like; Or Aspergillus Orizae ( Aspergillus orizae ), Aspergillus material ( Aspergillus sojae ), Monascus albidulus ( Monascus albidulus ), Monascus pilosus ( Monascus pilosus ), Monascus purpureus ), etc. Mold; may be used alone or in combination. As the strain, an isolated strain or a commercially available strain may be used without limitation.

In the present invention, when the black ginseng is fermented black ginseng, the filtrate or non-filtrate (ferment) of the fermented black ginseng extract may be used, but is not limited thereto.

As used herein, the term “filtrate” refers to a material from which precipitates or particles have been filtered. A method of obtaining the filtrate is not particularly limited, and may be filtered using a method known in the art, for example, a membrane, a filter, and the like.

As used herein, the term "ferment" refers to a material that is not filtered, but does not exclude unnecessary components included in the material, for example, cells or proteins, which are removed by centrifugation, precipitation, etc. .The filtrate or non-filtrate may be a filtrate or non-filtrate of a fermented material, but is not limited thereto.

As used herein, the term "red ginseng" refers to ginseng that has turned red by applying a special steaming, drying and processing process to fresh ginseng. It contains a large amount compared to fresh ginseng or white ginseng, and is known to generate unique ginsenosides. In the present invention, the red ginseng may be red ginseng itself or fermented red ginseng, but is not limited thereto.

The fermented red ginseng may be prepared by fermenting with a strain usable for conventional fermentation. The strain may be used without limitation as long as it is a strain used for fermentation known in the art, and may be, for example, lactic acid bacteria, yeast or mold. The strain is the same as described above.

In the present invention, when the red ginseng is fermented red ginseng, the filtrate or non-filtrate of the fermented red ginseng extract may be used, but is not limited thereto.

As used herein, the term “tyrosine” refers to an aromatic amino acid having a benzene ring in a molecule as a non-essential amino acid. The tyrosine may be D-form or L-form, and for the purposes of the present invention, it is preferably L-form, but is not limited thereto.

As used herein, the term "extract" refers to a liquid component obtained by immersing a target substance in various solvents and then extracting it for a certain time at room temperature, low temperature, or a heated state, and a product such as a solid obtained by removing the solvent from the liquid component. means In addition, in addition to the results, it can be comprehensively interpreted as including all of the dilutions of the results, their concentrates, their preparations, and their purified products.

In the present invention, the extract may be centella asiatica extract, oat extract, arnica extract, black ginseng extract or red ginseng extract. The extract can be extracted from various organs of natural, hybrid, and variegated plants of the target plant, and can be extracted from, for example, roots, above-ground parts, stems, leaves, flowers, body of fruits, skins of fruits, as well as plant tissues, It may be appropriately selected depending on the type of target plant, but is not limited thereto. The extract can be obtained by extraction with water or various organic solvents. At this time, the organic solvent used is not particularly limited as long as the extract can be obtained, but specifically water, a polar solvent or a non-polar solvent, and more specifically water, a lower alcohol having 1 to 6 carbon atoms ( As a C1 to C6 alcohol, it may be methanol, ethanol, propanol or butanol, etc.), or a mixed solvent thereof.

In addition, the method for obtaining the extract is not particularly limited as long as the extract can be obtained, but specifically, the roots, stems, leaves, fruits, flowers, Methods such as cold extraction, heating extraction, ultrasonic extraction, and reflux extraction using a reflux condenser can be used.

As used herein, the term “fraction” refers to a result obtained by performing fractionation in order to separate a specific component or a specific component group from a mixture including various components. In the present invention, the fraction may be a fraction of Centella asiatica extract, a fraction of an oat extract, a fraction of an arnica extract, a fraction of a black ginseng extract, or a fraction of a red ginseng extract.

The fractionation method for obtaining the fraction in the present invention is not particularly limited thereto, as long as the fraction can exhibit an effect of promoting beneficial skin bacteria, but may be performed according to a method commonly used in the art. For example, a solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed by passing through an ultrafiltration membrane having a constant molecular weight cut-off value, various chromatography (separation according to size, charge, hydrophobicity or affinity) It can be a chromatographic fractionation method for performing a chromatographic fractionation method, and a combination thereof.

In the present invention, the type of the fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvent include polar solvents such as water, distilled water, and alcohol; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more. When alcohol is used in the fractionation solvent, a lower alcohol having 1 to 4 carbon atoms (C1 to C4 alcohol) may be used.

The centella asiatica, oats, arnica, black ginseng and red ginseng may be cultivated or commercially available without limitation.

The composition of the present invention may be any selected from the group consisting of Centella asiatica extract or fractions thereof, oat extract or fractions thereof, arnica extract or fractions thereof, allantoin, black ginseng extract or fractions thereof, red ginseng extract or fractions thereof, tyrosine and combinations thereof. The one or more substances may be included in an amount of 0.0005 to 90% by weight (w/w), specifically 0.001 to 30% by weight (w/w) based on the total weight of the composition, but is not limited thereto.

As used herein, the term “beneficial skin bacteria” refers to a strain that helps relieve inflammation among skin flora, regulates psoriasis-related inflammation, inhibits the growth of harmful bacteria, and inhibits tumor growth. The skin beneficial bacteria may be, for example, Staphylococcus epidermidis , but is not limited thereto. The Stephylococcus epidermidis induces antimicrobial peptide (AMP) expression from epidermal cells of the skin and enhances the skin regeneration effect, thereby enhancing skin defense; When PSM (Phenol soluble modulin), a component secreted by S. epidermidis, is treated, it promotes skin regeneration by inhibiting cell membrane destruction (death) and growth of harmful bacteria; Butyric acid, a component secreted by Staphylococcus epidermidis, suppresses the expression of inflammatory factors induced by ultraviolet rays, thereby exhibiting a skin soothing effect; When live bacteria are applied to the skin, it exhibits an effect of enhancing skin moisture content and inhibiting moisture loss; When live cells are applied to the skin, the skin pH is slightly acidified and the pH environment can be improved; the substance having the effect of enhancing the beneficial bacteria, S. epidermidis, has a beneficial effect as a cosmetic composition. The "harmful bacteria" means bacteria that cause an inflammatory reaction or acne on the skin, for example, Propionibacterium acnes , Corynebacterium minutissimum ( Corynebacterium minutissimum ), Stephylococcus aureus Reus ( Staphlococcus aureus ) It may be, but is not limited thereto.

As used herein, the term "promoting beneficial skin bacteria" means promoting or improving the growth of the above-mentioned beneficial skin bacteria. For the purposes of the present invention, the promotion of the beneficial skin bacteria may be the promotion of S. epidermidis, but is not limited thereto.

Another aspect of the present invention provides a cosmetic composition comprising the composition.

In the present invention, the cosmetic composition comprises a solution, an external ointment, a cream, a foam, a nourishing lotion, a softening lotion, a pack, a softening water, an emulsion, a makeup base, an essence, a soap, a liquid detergent, a bath agent, a sunscreen cream, a sun oil, Suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays may be prepared in a formulation selected from the group consisting of, but not limited

In the present invention, the cosmetic composition may further include at least one cosmetically acceptable carrier to be formulated in general skin cosmetics, and as common ingredients, for example, oil, water, surfactant, humectant, lower alcohol , a thickener, a chelating agent, a colorant, a preservative, a fragrance, etc. may be appropriately mixed, but is not limited thereto.

The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation of the cosmetic composition.

When the formulation of the present invention is an ointment, paste, cream or gel, as a carrier component, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. may be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohard propellants such as, but not limited to, locarbon, propane/butane or dimethyl ether. These may be used alone or in combination of two or more.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer, or emulsifier may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan may be used, but are limited thereto doesn't happen These may be used alone or in combination of two or more.

When the formulation of the present invention is a suspension, as a carrier component a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters; Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a soap, alkali metal salt of fatty acid, fatty acid hemiester salt, fatty acid protein hydrolyzate, isethionate, lanolin derivative, aliphatic alcohol, vegetable oil, glycerol, sugar, etc. may be used as carrier components. can, but is not limited thereto. These may be used alone or in combination of two or more.

The cosmetic composition of the present invention is selected from the group consisting of Centella asiatica extract or fraction thereof, oat extract or fraction thereof, arnica extract or fraction thereof, allantoin, black ginseng extract or fraction thereof, red ginseng extract or fraction thereof, tyrosine and combinations thereof. Any one or more substances may be included in an amount of 0.0005 to 90% by weight (w/w), specifically 0.001 to 30% by weight (w/w) based on the total weight of the composition, but is not limited thereto.

Another aspect of the present invention provides a pharmaceutical composition for promoting beneficial skin bacteria comprising the composition.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition, and the carrier may include a non-naturally occurring carrier. . The carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In addition, the pharmaceutical composition is prepared according to a conventional method for each tablet, pill, powder, granule, capsule, suspension, internal solution, emulsion, syrup, sterilized aqueous solution, non-aqueous solution, suspension, emulsion, lyophilized formulation, transdermal It can be formulated and used in the form of absorbents, gels, lotions, ointments, creams, patches, cataplasmas, pastes, sprays, skin emulsions, skin suspensions, transdermal delivery patches, drug-containing bandages or suppositories.

Specifically, in the case of formulation, it may be prepared using a diluent or excipient such as a filler, a weight agent, a binder, a wetting agent, a disintegrant, a surfactant, etc. commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation may be prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. It can be prepared by adding various excipients, for example, a wetting agent, a sweetening agent, a fragrance, a preservative, and the like, in addition to the oral liquid and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. As the base of the suppository, Witepsol, Macrogol, Tween 61, cacao butter, laurin, glycerogelatin, etc. may be used.

The pharmaceutical composition of the present invention is selected from the group consisting of Centella asiatica extract or fraction thereof, oat extract or fraction thereof, arnica extract or fraction thereof, allantoin, black ginseng extract or fraction thereof, red ginseng extract or fraction thereof, tyrosine and combinations thereof. Any one or more substances may be included in an amount of 0.0005 to 90% by weight (w/w), specifically 0.001 to 30% by weight (w/w) based on the total weight of the composition, but is not limited thereto.

The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type and severity of the subject, age, sex, activity of the drug, Sensitivity to the drug, time of administration, route of administration and rate of excretion, duration of treatment, factors including concomitant drugs, and other factors well known in the medical field. For example, the pharmaceutical composition may be administered at a dose of 0.01 to 500 mg/kg per day, specifically 10 to 100 mg/kg, and the administration may be administered once a day or divided several times.

The pharmaceutical composition may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, and can be easily determined by those skilled in the art.

In addition, the pharmaceutical composition may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method, and the dosage may vary depending on the patient's condition and weight, and the degree of disease. , depending on the drug form, administration route and time, but may be appropriately selected by those skilled in the art.

In an embodiment of the present invention, it was confirmed that the Centella asiatica extract, oat kernel extract, arnica flower extract, allantoin, black ginseng extract, red ginseng extract and/or tyrosine according to the present invention exhibited a skin beneficial bacteria enhancing effect of up to 23.3%, 2 When mixing the materials of the species, it was confirmed that the beneficial bacteria enhancing effect was increased compared to the single material, and when 7 types of materials were mixed, it was confirmed that up to 30.3% of the beneficial bacteria enhancing effect of the skin was shown. Since it was confirmed that a synergistic effect was exhibited without an effect of attenuating each other when mixing the above materials, it can be applied as a composition for promoting beneficial skin bacteria.

Centella asiatica extract, oat extract, arnica extract, allantoin, black ginseng extract, red ginseng extract, tyrosine, and combinations thereof according to the present invention exhibit an effect of promoting beneficial skin bacteria, and thus can be provided as a cosmetic composition or pharmaceutical composition for promoting beneficial skin bacteria.

Hereinafter, the present invention will be described in more detail by way of Examples. However, these examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited by these examples, and it will be apparent to those of ordinary skill in the art to which the present invention pertains.

Example 1. Selection of skin beneficial bacteria

Among the various skin flora, Staphylococcus epidermidis ( S. epidermidis ) has the same effect as in Table 1 below, and selected as beneficial skin bacteria and materials that increase them were selected in the Examples below.

skin flora human influence mechanism of action indicator substance references S. epidermidis relieve inflammation By regulating FFAR2 (Free fatty acid receptor 2) mechanism, UVB-induced cytokine enhancement is suppressed Butyric acid One) Controlling psoriasis-related inflammation Regulate the expression of A20, an inflammatory regulatory protein, in the host N/A 2) tumor growth inhibition Selective inhibition of DNA polymerase activity in central cells 6-N-hydroxyaminopurine (6-HAP) 3)

1) Butyric acid from probiotic = Staphylococcus epidermidis = in the skin microbiome down-regulates the ultraviolet-induced pro-inflammatory IL-6 cytokine via short-chain fatty acid receptor (2019) International Journal of Molecular sciences 20:4477.

2) Staphylococcus epidermidis-induced Interleukin-1 beta and human beta-defensin-2 expression in human keratinocytes is regulated by the host molecule A20 (TNFAIP3) (2019) Acta Dermato-Venereologica 99:181-187.

3) A commensal strain of Staphylococcus epidermidis protects against skin neoplasia (2018) Science Advances 4:eaao4502.

Example 2. Test of the skin beneficial bacteria enhancement effect of the selected material

Centella asiatica, oats, arnica, allantoin, black ginseng, red ginseng and tyrosine were selected as materials that can exhibit the effect of promoting beneficial skin bacteria and prepared as follows.

Specifically, Centella asiatica extract was obtained by drying and shredding Centella asiatica leaves (purchased at the medicinal market), then put 100 g of dry weight in a flask, and extracted with 1000 g of extraction solvent (distilled water: ethanol = 3:7) for 3 days at room temperature. The extract was filtered through a filter having a pore size of 0.2 μm to prepare a Centella asiatica extract.

The oat extract was dried and shredded oat kernels (purchased at the drug market), 100 g of dry weight was placed in a flask, and 1000 g of an extraction solvent (distilled water: ethanol = 3:7) was extracted at room temperature for 3 days. The extract was filtered through a filter having a pore size of 0.2 μm to prepare an oat kernel extract.

Arnica extract was dried and chopped arnica flowers (purchased at the drug market), 100 g of dry weight was placed in a flask, and 1000 g of an extraction solvent (distilled water: ethanol = 3:7) was extracted at room temperature for 3 days. The extract was filtered through a filter having a pore size of 0.2 μm to prepare an arnica flower extract.

Black ginseng extract was dried and chopped, 100 g of dry weight was placed in a flask, and extracted with 1000 g of extraction solvent (distilled water: ethanol = 3:7) for 3 days at room temperature. The extract was filtered through a filter having a pore size of 0.2 μm to prepare a black ginseng extract.

After red ginseng extract was dried and chopped, 100 g of dry weight was placed in a flask and extracted with 1000 g of an extraction solvent (distilled water: ethanol = 3:7) for 3 days at room temperature. The extract was filtered through a filter having a pore size of 0.2 μm to prepare a red ginseng extract.

Allantoin or tyrosine was used by purchasing a commercially available reagent.

A sterile liquid medium was prepared using a commercial TSB (Tryptic soy broth) medium. S. epidermidis glycerol stock solution was inoculated into sterile liquid TSB medium, and pre-cultured at 30-37° C. for 6-18 hours. This pre-culture was performed 1-2 times as needed. 0.1-10% of each of the previously prepared samples to be evaluated (centella asiatica extract, oat kernel extract, arnica flower extract, allantoin, black ginseng, red ginseng, tyrosine) to be evaluated in the sterile liquid TSB medium, and inoculated with the pre-culture solution, Incubated at 30-37°C for 6-18 hours. Glucose was added as a positive control. After incubation, the absorbance immediately after inoculation and the absorbance during the stationary phase were measured, and the ratio (growth rate) of the values was used as a statistical variable. By comparing the growth rate of the experimental group treated with the sample compared to the control group not treated with the sample, it was determined whether the sample had a significant effect on the growth of bacteria. Evaluation was performed 3-6 times or more, and after calculating the average value and standard deviation of the growth rates of multiple samples, the significance was verified through the t-test.

As a result, as shown in Table 2 below, centella asiatica extract, oat kernel extract, arnica flower extract, allantoin, black ginseng extract, red ginseng extract, or tyrosine showed an effect of enhancing skin beneficial bacteria by more than 4.5% and up to 23.3%.

Material Beneficial bacteria enhancement effect (%) Glucose (positive control) 12.5 Centella asiatica extract 15.2 oat kernel extract 13.9 Arnica Flower Extract 23.3 allantoin 20.3 Black Ginseng Extract 10.2 Red Ginseng Extract 6.8 tyrosine 4.5%

Example 3. Test of the skin beneficial bacteria enhancement effect of the material mixture

The beneficial bacteria enhancing effect according to the combination of Centella asiatica extract, oat kernel extract, arnica flower extract, allantoin, black ginseng extract, red ginseng extract or tyrosine prepared in Example 2 was confirmed in the same manner as in Example 2.

As a result, as shown in Table 3 below, when two or more types of materials were mixed, the beneficial bacteria enhancing effect was 15% or more, up to 27.7%, and when 7 types of materials were mixed in the same ratio, 30.3% and 7 types of materials were mixed. When the material was mixed with extract: single ingredient = 2:1, it showed a beneficial bacteria enhancement effect of 28.8%.

material mixture Beneficial bacteria enhancement effect (%) material mixture Beneficial bacteria enhancement effect (%) Centella asiatica extract + Arnica flower extract (same ratio) 23.7 Arnica flower extract + black ginseng extract (same ratio) 26.8 Centella asiatica extract + Allantoin (same ratio) 22.0 Arnica flower extract + red ginseng extract (same ratio) 26.8 Centella asiatica extract + black ginseng extract (same ratio) 15.8 Arnica Flower Extract + Tyrosine (equal ratio) 26.6 Centella asiatica extract + red ginseng extract (same ratio) 15.9 Allantoin + Black Ginseng Extract (same ratio) 22.5 Centella asiatica extract + tyrosine (same ratio) 16.0 Allantoin + Red Ginseng Extract (same ratio) 22.4 Oat kernel extract + Arnica flower extract (equal ratio) 25.0 Allantoin + Tyrosine (equal ratio) 22.6 Oat kernel extract + Allantoin (same ratio) 22.2 Black ginseng extract + red ginseng extract (same ratio) 15.7 Oat kernel extract + black ginseng extract (same ratio) 15.9 Black ginseng extract + tyrosine (same ratio) 12.3 Oat kernel extract + red ginseng (same ratio) 15.7 Red Ginseng Extract + Tyrosine (same ratio) 12.7 Oat kernel extract + tyrosine (equal ratio) 15.0 Mix of 7 types (same ratio) 30.3 Arnica Flower Extract + Allantoin (equal ratio) 27.7 7 types of mixture (extract: single ingredient = 2:1 ratio) 28.8

From the results of the above examples, it was confirmed that centella asiatica extract, oat kernel extract, arnica flower extract, allantoin, black ginseng extract, red ginseng extract or tyrosine exhibited a skin beneficial bacteria enhancing effect of up to 23.3%. In addition, it was confirmed that when two types of materials were mixed, the beneficial bacteria enhancing effect was increased compared to the single material, and when 7 types of materials were mixed, it was confirmed that up to 30.3% of the skin beneficial bacteria enhancing effect was exhibited. It was confirmed that a synergistic effect was exhibited without the effect of attenuating each other when more than one type of material was mixed. These results suggest that the material of the present invention can be applied as a composition for promoting beneficial skin bacteria either alone or by mixing.

The composition for promoting beneficial skin bacteria according to the present invention promotes the beneficial skin bacteria, S. epidermidis, and the S. epidermidis induces antimicrobial peptide (AMP) expression from epidermal cells of the skin and has a skin regeneration effect. by promoting skin defense (Staphylococcus epidermidis: A potential new player in the physiopathology of acne? (2019) Dermatology 235:287-294); When PSM (Phenol soluble modulin), a component secreted by S. epidermidis, is treated, it promotes skin regeneration by inhibiting cell membrane destruction (death) and growth of harmful bacteria (Selective antimicrobial action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal resident of the skin (2010) Journal of Investigative Dermatology 130:192-200); Butyric acid, a component secreted by Staphylococcus epidermidis, suppresses the expression of inflammatory factors induced by ultraviolet rays, resulting in a skin soothing effect. pro-inflammatory IL-6 cytokine via short-chain fatty acid receptor (2019) International Journal of Molecular sciences 20:4477); When live bacteria are applied to the skin, it has the effect of increasing skin moisture content and inhibiting moisture loss (Pilot study on novel skin care method by augmentation with Staphylococcus epidermidis, an autologous skin microbe - A blinded randomized clinical trial (2015) Journal of Dermatological Science 79: 119-126 (doi: 10.1016/j.jdermsci.2015.05.001)); When live cells are applied to the skin, the skin pH is slightly acidified and the pH environment is improved (Pilot study on novel skin care method by augmentation with Staphylococcus epidermidis, an autologous skin microbe - A blinded randomized clinical trial (2015) Journal of Dermatological Science 79: 119-126 (doi: 10.1016/j.jdermsci.2015.05.001));

From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the following claims and their equivalents.

Claims (5)

A composition for promoting beneficial skin bacteria, comprising tyrosine as an active ingredient.
According to claim 1, wherein the skin beneficial bacteria is Staphylococcus epidermidis ( Staphylococcus epidermidis ), the composition.
The composition of claim 1, wherein the composition further comprises a Centella asiatica extract or a fraction thereof, or allantoin.
A cosmetic composition comprising the composition of any one of claims 1 to 3.
A pharmaceutical composition for promoting beneficial skin bacteria comprising the composition of any one of claims 1 to 3.